Masimo (NASDAQ:MASI) had its target price raised by UBS Group from $190.00 to $207.00 in a report released on Thursday, BenzingaRatingsTable reports. They currently have a buy rating on the medical equipment provider’s stock.
A number of other equities analysts have also recently weighed in on the company. BidaskClub raised Masimo from a buy rating to a strong-buy rating in a report on Wednesday, January 22nd. Piper Sandler reissued a buy rating and issued a $175.00 price target on shares of Masimo in a report on Wednesday, January 15th. Finally, Piper Jaffray Companies reissued an overweight rating and issued a $175.00 price target (up from $161.00) on shares of Masimo in a report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $177.36.
NASDAQ MASI opened at $178.37 on Thursday. Masimo has a fifty-two week low of $118.93 and a fifty-two week high of $186.91. The stock has a market cap of $9.51 billion, a price-to-earnings ratio of 51.85, a price-to-earnings-growth ratio of 2.18 and a beta of 1.11. The business has a fifty day moving average of $171.39 and a 200-day moving average of $156.20.
In other news, EVP Thomas Samuel Mcclenahan sold 500 shares of Masimo stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $159.29, for a total value of $79,645.00. Following the completion of the sale, the executive vice president now owns 5,607 shares of the company’s stock, valued at $893,139.03. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $175.00, for a total value of $1,750,000.00. Following the completion of the sale, the director now directly owns 76,245 shares of the company’s stock, valued at approximately $13,342,875. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,378 shares of company stock valued at $9,435,640. Company insiders own 11.50% of the company’s stock.
Several large investors have recently made changes to their positions in MASI. Great Diamond Partners LLC purchased a new stake in Masimo during the fourth quarter valued at about $29,000. Flagship Harbor Advisors LLC grew its position in Masimo by 45.7% during the third quarter. Flagship Harbor Advisors LLC now owns 236 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 74 shares during the period. West Oak Capital LLC grew its position in Masimo by 62.5% during the fourth quarter. West Oak Capital LLC now owns 325 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 125 shares during the period. Procyon Private Wealth Partners LLC purchased a new stake in Masimo during the fourth quarter valued at about $54,000. Finally, Exchange Traded Concepts LLC purchased a new stake in Masimo during the fourth quarter valued at about $71,000. 84.20% of the stock is owned by institutional investors and hedge funds.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Read More: Dividend Achievers
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.